Our next step in the development of 800CW-TATE for MFGS in meningiomas will be the clinical evaluation of this tracer in patients with intracranial meningiomas, aiming to add another SSTR2-directed approach to the treatment of this type of tumors. This evidence concerns the gene SSTR2 and intracranial meningioma.